Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2019-03-11 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2019-03-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes announcements of financial results for the fourth quarter and fiscal year ended December 31, 2018, but it does not contain the full financial statements or detailed financial analysis itself. Instead, it references a press release (Exhibit 99.1) that is furnished with the report. Additionally, it announces the departure of a Chief Medical Officer, which is a management change. The document is relatively short (4236 characters) and serves as an announcement of events rather than a full report. According to the rules, such documents are classified as Regulatory Filings (RNS) because they do not contain the full annual or quarterly report, nor are they solely about management changes (which would be MANG), but a combination of announcements in a current report format. Therefore, the best classification is Regulatory Filings (RNS).
2019-03-11 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes the entry into a material definitive agreement, specifically an office lease agreement, including detailed lease terms and obligations. There is no financial statement or comprehensive financial data presented, nor is it an earnings release or annual/interim report. The document is not a report publication announcement or certification. It is a regulatory filing disclosing a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 4135 characters, which is consistent with a typical 8-K filing length and not a full report.
2019-02-15 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-14 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-13 English
SC 13G/A
Major Shareholding Notification
2019-02-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.